Wolfe Research upgraded Edwards Lifesciences (EW) to Outperform from Peer Perform with a $92 price target. Checks suggest Medtronic’s (MDT) long-term Evolut TAVR data “flop” in February sets Edwards up for material share gain, the analyst tells investors. Following Medtronic’s news, the firm raised Edwards estimates to the top end of short-to-mid-run guidance ranges, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences: TRISCEND II Data and EVOQUE Differentiation Underpin Buy Rating and Long-Term Growth Outlook
- Edwards Lifesciences announces new data on EVOQUE TTVR system
- Oppenheimer downgrades AtriCure on new competition from Edwards
- Early notable gainers among liquid option names on February 17th
- Edwards Lifesciences price target lowered to $90 from $94 at UBS